<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097794</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FMS-CT-118</org_study_id>
    <nct_id>NCT05097794</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between &quot;BR1015-1&quot; and &quot;BR1015-2&quot; in Healthy Volunteers</brief_title>
  <official_title>An Open-label, One-sequence, 3-period Study to Evaluate Drug-drug Interactions and Safety Between &quot;BR1015-1&quot; and &quot;BR1015-2&quot; in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacokinetic interactions (Drug-Drug interaction)&#xD;
      and safety between &quot;BR1015-1&quot; and &quot;BR1015-2&quot; in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      *Study Objective: After repeated administration of BR1015-1 and BR1015-2 for healthy&#xD;
      volunteers, the pharmacokinetic interactions and safety are evaluated.&#xD;
&#xD;
      *Investigational Product (and regimen)&#xD;
&#xD;
        1. BR1015-1: Administration of BR1015-1 60 mg once a day for 5 days&#xD;
&#xD;
        2. BR1015-2: Administration of BR1015-2 1.5 mg once a day for 5 days&#xD;
&#xD;
        3. BR1015-1+BR1015-2: Co-administration of BR1015-1 60 mg and BR1015-2 1.5 mg once a day&#xD;
           for 5 days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">October 22, 2021</completion_date>
  <primary_completion_date type="Actual">September 24, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>One-sequence, 3-period study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[Part A] Cmax,ss of BR1015-1</measure>
    <time_frame>0~24 hour after administration at Day 5.</time_frame>
    <description>Pharmacokinetic variables - Maximum (peak) plasma concentration of BR1015-1 at steady state (Cmax,ss).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part B] Cmax,ss of BR1015-2</measure>
    <time_frame>0~24 hour after administration at Day 5.</time_frame>
    <description>Pharmacokinetic variables - Maximum (peak) plasma concentration of BR1015-2 at steady state (Cmax,ss).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part A] AUCtau of BR1015-1</measure>
    <time_frame>0~24 hour after administration at Day 5.</time_frame>
    <description>Pharmacokinetic variables - Area under the plasma drug concentration-time curve to the end of the dosing period in multiple dosing of BR1015-1 at steady state. (AUCtau,ss)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[Part B] AUCtau of BR1015-2</measure>
    <time_frame>0~24 hour after administration at Day 5.</time_frame>
    <description>Pharmacokinetic variables - Area under the plasma drug concentration-time curve to the end of the dosing period in multiple dosing of BR1015-2 at steady state. (AUCtau,ss)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>[Part A] AUClast of BR1015-1</measure>
    <time_frame>0~48 hour after administration</time_frame>
    <description>Area under the plasma drug concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration (AUClast) of BR1015-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part B] AUClast of BR1015-2</measure>
    <time_frame>0~48 hour after administration</time_frame>
    <description>Area under the plasma drug concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration (AUClast) of BR1015-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A] AUCinf of BR1015-1</measure>
    <time_frame>0~48 hour after administration</time_frame>
    <description>Area under the plasma drug concentration-time curve over the time interval from 0 extrapolated to infinity of BR1015-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part B] AUCinf of BR1015-2</measure>
    <time_frame>0~48 hour after administration</time_frame>
    <description>Area under the plasma drug concentration-time curve over the time interval from 0 extrapolated to infinity of BR1015-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A] Tmax of BR1015-1</measure>
    <time_frame>0~24 hour after administration</time_frame>
    <description>Time to reach maximum (peak) plasma concentration following drug administration at steady state (Tmax,ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part B] Tmax of BR1015-2</measure>
    <time_frame>0~24 hour after administration</time_frame>
    <description>Time to reach maximum (peak) plasma concentration following drug administration at steady state (Tmax,ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part A] t1/2 of BR1015-1</measure>
    <time_frame>0~48 hour after administration</time_frame>
    <description>Terminal half-life of BR1015-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[Part B] t1/2 of BR1015-2</measure>
    <time_frame>0~48 hour after administration</time_frame>
    <description>Terminal half-life of BR1015-2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sequence BR1015-1/BR1015-2/BR1015-1 + BR1015-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 32 subjects will be enrolled in one sequence group. The investigational products (IPs) will be administered according to the treatment groups(BR1015-1, BR1015-2, BR1015-1 + BR1015-2) assigned to one sequence group in Period 1, Period 2, and Period 3.&#xD;
Period 1(BR1015-1): BR1015-1(Fimasartan 60mg) - 1 tablet QD, five-day repeated-dose&#xD;
Period 2(BR1015-2): BR1015-2(Indapamide 1.5mg) - 1 tablet QD, five-day repeated-dose&#xD;
Period 3(BR1015-1 + BR1015-2): BR1015-1 (Fimasartan 60mg) 1 tablet + BR1015-2 (Indapamide 1.5mg) 1 tablet QD, five-day repeated-dose&#xD;
Washout period between Period 1 and Period 2: five days&#xD;
Washout period between Period 2 and Period 3: two days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR1015-1</intervention_name>
    <description>- Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.</description>
    <arm_group_label>Sequence BR1015-1/BR1015-2/BR1015-1 + BR1015-2</arm_group_label>
    <other_name>Fimasartan 60 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR1015-2</intervention_name>
    <description>- Administration to the BR1015-2 group: 1.5 mg of BR1015-2 will be administered one tablet once a day, five-day repeated doses.</description>
    <arm_group_label>Sequence BR1015-1/BR1015-2/BR1015-1 + BR1015-2</arm_group_label>
    <other_name>Indapamide 1.5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR1015-1 + BR1015-2</intervention_name>
    <description>- Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.</description>
    <arm_group_label>Sequence BR1015-1/BR1015-2/BR1015-1 + BR1015-2</arm_group_label>
    <other_name>Fimasartan and Indapamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects are given sufficient explanations about the trial objectives and contents as&#xD;
             well as properties of investigational drugs before participating in the trial, and&#xD;
             will voluntarily express their consent by signing an IRB-approved written consent to&#xD;
             participate in the trial.&#xD;
&#xD;
          -  Healthy adults aged 19 to 55 years at screening.&#xD;
&#xD;
          -  The subject's weight is 50 kg or more for males, 45 kg or more for females, and body&#xD;
             mass index (BMI) is 18.0 or more but 30.0 kg/m2 or less.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have history of clinically significant diseases including hypersensitivity&#xD;
             reaction, intolerability and anaphylaxis to major ingredients and other ingredients of&#xD;
             investigational products.&#xD;
&#xD;
          -  Those who have history of clinically significant diseases including allergy reaction&#xD;
             to Yellow No. 5 (Sunset Yellow FCF).&#xD;
&#xD;
          -  Those who have a history of clinically significant diseases related to liver, kidney,&#xD;
             digestive system, respiratory system, musculoskeletal system, endocrine system,&#xD;
             neuropsychiatric system, hemato-oncology system, cardiovascular system (including&#xD;
             orthostatic hypotension), etc.&#xD;
&#xD;
          -  Those who have medical history of gastrointestinal system diseases (for example:&#xD;
             Crohn's disease, peptic ulcer disease, etc.) and operations that may influence the&#xD;
             absorption of investigational drugs. (However, appendectomy, hernia operation,&#xD;
             endoscopic polypectomy and hemorrhoids/anal fissure/anal fistula surgeries are&#xD;
             excluded.)&#xD;
&#xD;
          -  Those with abnormal findings from the screening tests (medical interview, vital signs,&#xD;
             electrocardiography, physical checkup, blood test, urinalysis, etc.) are judged to&#xD;
             have clinical significance.&#xD;
&#xD;
          -  Those who are positive to HBsAg, HCV Ab, HIV Ab, VDRL tests at screening.&#xD;
&#xD;
          -  Those with any of the following results at screening:&#xD;
&#xD;
          -  AST or ALT &gt; twice the upper limit of normal range&#xD;
&#xD;
          -  T. bilirubin &gt; twice the upper limit of normal range&#xD;
&#xD;
          -  Estimated glomerular filtration rate (e-GFR) &lt; 60 mL/min/1.73m2 (CKD-EPI method used)&#xD;
&#xD;
          -  Na &gt; 150 mEq/L or &lt;130 mEq/L&#xD;
&#xD;
          -  K &gt; 5.5 mEq/L or &lt;3.0 mEq/L&#xD;
&#xD;
          -  Those with systolic blood pressure &gt; 160 mmHg or &lt; 110 mmHg, or diastolic blood&#xD;
             pressure &gt; 100 mmHg or &lt; 70 mmHg from vital signs at screening.&#xD;
&#xD;
          -  Others who are judged to be ineligible to participate in the trial by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>An-Hye Kim, M.D. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Seongnam-si</state>
        <zip>13520</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 17, 2021</study_first_submitted>
  <study_first_submitted_qc>October 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 17, 2021</last_update_submitted>
  <last_update_submitted_qc>October 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

